Myeloma: making sense of a complex blood cancer | Zendy

Mary Kelly | Zendy; Teresa Meenaghan | Zendy; Maura Dowling | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Myeloma: making sense of a complex blood cancer

Author(s) -

Mary Kelly,

Teresa Meenaghan,

Maura Dowling

Publication year - 2010

Publication title -

british journal of nursing

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.269

H-Index - 48

eISSN - 2052-2819

pISSN - 0966-0461

DOI - 10.12968/bjon.2010.19.22.1415

Subject(s) - pomalidomide , multiple myeloma , medicine , thalidomide , lenalidomide , bortezomib , intensive care medicine , hypercalcaemia , quality of life (healthcare) , ixazomib , cancer , oncology , carfilzomib , nursing , calcium

Myeloma is a challenging blood cancer characterized by bone destruction, hypercalcaemia, renal insufficiency and anaemia. Although myeloma remains incurable, recent advancements in treatments have resulted in significant improvements in morbidity. The use of immunomodulatory drugs-thalidomide, lenalidomide, pomalidomide (in clinical trials)-and the proteasome inhibitor, bortezomib, in conjunction with conventional chemotherapy and supportive therapies, have resulted in a significant shift in approaches to treatment and an improvement in patients' quality of life. Nurses must remain up-to-date with current treatments for myeloma and their related side-effects. In addition, nurses play a key role in the coordination of a multidisciplinary approach to care for myeloma patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research